Biomanufacturing FOAK: What Makes the First Industrial Plant Different

A first commercial biomanufacturing plant is different because the biology now depends on a set of project interfaces that laboratory evidence barely touched. Feedstock, fermentation assets, downstream processing, utilities, commissioning and offtake each carry their own risk, and each one can move the plant economics. The general first-of-a-kind (FOAK) questions of risk, offtake and financing are covered in what FOAK means in climate tech and from FOAK to NOAK. This article covers the interfaces specific to biomanufacturing.

The product gives the plant a reason to exist

A plant earns capital when someone needs its output. Before any engineering slide, the story should name the buyer, the specification that matters, the viable price range, the material the product displaces and the qualification that has already happened. The product and buyer questions are set out in industrial biotech positioning. Everything below assumes that case is made, because the plant inherits every gap in it.

Feedstock is a contract, and a resource base is a hypothesis

Many biological processes depend on a feedstock whose cost, composition, geography and availability shape the plant economics. Founders often describe that feedstock as waste, renewable or abundant. The project still has to state the delivered cost, the contracts behind it, the quality variation the process can tolerate and the volume available at the site. Lenders price secured supply and treat a theoretical resource base as a hypothesis.

Feedstock variation also reaches into the biology. A sugar stream, a gas mix or a residue that shifts in composition changes what the organism experiences. Say which feedstock specification the process has run on, over how many batches, and what the plant does when a delivery falls outside it.

Fermentation assets bring their own risk class

A large bioreactor is a less uniform place than a small one. As vessels grow, cells travel through zones with different concentrations of substrate, dissolved oxygen and pH, and they respond to those swings. Researchers studying a recombinant Corynebacterium glutamicum process used scale-down experiments to show that loss of homogeneity leads to lower levels of cadaverine production. The organism was the same. The environment it experienced was different.

Contamination risk grows with vessel size, run length and the number of transfers from seed train to production vessel. A contaminated batch at commercial scale costs a full vessel of output, a cleaning and validation cycle and possibly a late delivery to a customer who qualified you on reliability. Put the contamination record at the largest scale run so far in the deck, and put the batch failure rate in the financial model. A model that assumes every batch succeeds tells a diligence team that nobody has run one yet.

Titre, yield and productivity connect these assets to the balance sheet. Titre drives vessel volume and downstream load. Yield drives feedstock cost. Productivity drives how many vessels you need to buy. Each number has a pilot value, a FOAK design value and a NOAK target, and the three should never share a column. Label which figures are measured, which are vendor quotes, which are contracted and which are model assumptions.

Downstream processing belongs in the headline

Fermentation gets the attention. Recovery and purification often carry a large share of capital and operating cost, and their share rises as titres fall or purity specifications tighten. Separation, concentration, drying and polishing each bring equipment, energy, yield losses and quality risk. A food or feed ingredient carries a different purity burden from a commodity chemical, and that difference shows up in the downstream train.

Put downstream evidence next to fermentation evidence. State the recovery yield achieved at scale, the purity reached and the steps that have run on production-type equipment. A strong titre with an untested purification route is half a process.

Utilities, site and commissioning

The first commercial facility has a real location. Steam, cooling water, power, compressed air, process water and effluent treatment all have a cost and a capacity at that site, and fermentation is heavy on several of them. Heat removal from large aerobic vessels is a design constraint in its own right. Company-level target economics need to be reconciled with these project-level figures, and the reconciliation belongs in the investor pack.

Commissioning is where the biology meets the plant for the first time. Sterility checks, water runs, seed train qualification and the first production batches all take time, and the ramp to nameplate capacity usually takes longer than the first model assumed. State the ramp profile, the working capital it consumes and who carries the cost of a slow start. Biotech founders often have deep process knowledge and less experience delivering large projects. Explain how engineering, procurement, construction, commissioning and operations capability enters the team, whether through hires, an engineering partner or an operator.

Offtake connects the product to the project

A credible buyer commitment reduces demand uncertainty. In biomanufacturing it can also define the product specification, the qualification plan and the volume ramp the plant is built around. The contract type decides how much weight it carries. A non-binding letter of interest and a long-term purchase agreement sit at opposite ends of the range, and investors will read the difference. Use the exact commercial status, and link the offtake terms to the ramp. Policy points the same way. The European Commission's 2026 bioeconomy measures connect new biobased manufacturing capacity with demand commitments and offtake. The wider mechanics are covered in what offtake means for FOAK climate tech.

Contract capacity or your own plant

Many biomanufacturing companies choose between renting fermentation capacity from a contract manufacturer (CDMO) and building their own plant. Contract capacity reduces capital need and reaches customers sooner. It also brings scheduling risk, technology transfer effort and shared margin. An owned plant gives control and long-term margin at the cost of capital, construction risk and a longer path to first product.

Liberation Labs sits in the middle of this choice. It broke ground on its first purpose-built precision fermentation biomanufacturing facility in Richmond, Indiana, and in 2025 it announced a manufacturing partnership with Vivici, a precision fermentation dairy protein company. For Vivici, the partnership is a route to volume without owning a plant. For the facility, a named product partner is evidence of demand for its capacity. If you plan to start in contract capacity and move to an owned plant, name the trigger for the switch, whether a volume, a margin threshold or a customer commitment.

What plant one must teach plant two

The first plant should show what can be standardised for the second. For biomanufacturing that means the fermentation train and vessel sizes, the seed and media preparation, the downstream sequence, the sterility and cleaning regime, the feedstock specification, the utility design and the operating procedures. Some costs are one-off learning. Others will repeat. Separating them is what makes a cost-down curve believable. Before you present the project, check that the story passes these tests with evidence.

• The feedstock specification, delivered cost and supply contract are stated.
• The largest scale run, its duration and its titre, yield and productivity are labelled as measured.
• The batch failure rate and downstream recovery yield sit inside the financial model.
• Site utilities and the commissioning ramp are costed, with named delivery capability.
• The offtake status is stated exactly and tied to the ramp.
• The capacity route, and what plant one standardises for plant two, are explicit.

When the plant story is ready to meet investors, our pitch and investor narrative work builds the deck and the project case around it.

Sources and further reading

• Scale-down experiments on a recombinant Corynebacterium glutamicum process, loss of homogeneity and cadaverine production, PMC
• Liberation Labs announces manufacturing partnership with Vivici, GlobeNewswire, 2025
• Liberation Labs breaks ground on first purpose-built precision fermentation biomanufacturing facility, Yahoo Finance
• Commission steps up action on EU bioeconomy, European Commission, 2026